Condition: Gastric Intestinal Metaplasia · Sponsor: Yongquan Shi
The goal of this clinical trial is to investigate the efficacy of ursodeoxycholic acid in treating gastric intestinal metaplasia in Helicobacter pylori-negative adults. It will also learn about the safety of ursodeoxycholic acid. The main questions it aims to answer are: Does ursodeoxycholic acid promote the regression of IM in individuals without Helicobacter pylori infection? What medical problems do participants experience when taking ursodeoxycholic acid? Researchers will compare ursodeoxycholic acid to a placebo (a look-alike substance that contains no drug) to see if ursodeoxycholic acid is effective in treating gastric intestinal metaplasia. Participants will: Take ursodeoxycholic acid or a placebo every day for 6 months. Visit the clinic once every 4 weeks for checkups and tests.
This description comes directly from the study's public registry record.
Yongquan Shi · 0086 + 02984771515 · shiyquan@fmmu.edu.cn
Always discuss trial participation with your own doctor first.
| 989 Hospital of PLA Joint Logistics Support Force | Pingdingshan, Henan, China | Recruiting |
| Ankang Central Hospital | Ankang, Shaanxi, China | Recruiting |
| Hanzhong 3201 Hospital | Hanzhong, Shaanxi, China | Recruiting |
| Shangluo Central Hospital | Shangluo, Shaanxi, China | Recruiting |
| Xijing hospital | Xi'an, Shaanxi, China | Recruiting |
| Xi'an Central Hospital | Xi'an, Shaanxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06610760